Health Economics›Glioblastoma›First-line therapy elderly or poor performance status patients

First-line therapy elderly or poor performance status patients

Glioblastoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Temozolomide and low-dose RT Variant #01	—	R 7 726	21d	—	9.3 mo	1	R 7 726 PFS proxy	1
Temozolomide monotherapy Variant #02	—	R 3 434	14d	—	8.3 mo	27	R 92 712 PFS proxy	2
Radiation therapy N/A - radiation	—	—	49d	—	7.5 mo	—	—	7

3 of 3 regimens shown